Cardiovascular

Latest News

Abelacimab Demonstrates Safety and Efficacy for Patients With AFib of All Ages: Sid Patel, MD

By Kyle Munz
Siddharth M. Patel, MD, MPH

April 24th 2025

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated Sid Patel, MD.

One's ZIP code can greatly influence care access | image credit: Syda Productions - stock.adobe.com

"The Barriers Are Real": Antoine Keller, MD, on Geography and Cardiovascular Health

By Kyle Munz
Antoine Keller, MD, FACC, FACS

April 18th 2025

Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD

By Kyle Munz
Jeremy Wigginton, MD

April 8th 2025

High-Impact Trials at ACC.25 Signal Shift in Chronic Disease Treatment

By Giuliana Grossi
Christian Ruff, MD

April 4th 2025

Heart disease is, and has been, the number 1 cause of death for Americans over the last century | image credit: Thirakun - stock.adobe.com

Digital Solutions Can Transform CVD Care, Prevention

By Kyle Munz

April 2nd 2025

Lipoprotein(a) and Cardiovascular Risk

Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.

Watch Now

Continuing Medical Education

View All

April 25th 2025

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases

April 25th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

April 25th 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology

More News

February 15th 2017

In Light of SPRINT, How to Treat Hypertension?

Mary Caffrey

An author in JAMA points out some caveats to a ground-breaking trial.

February 4th 2017

FOURIER Study Finds Repatha Reduces Risk of Cardiovascular Events

Laura Joszt, MA

Amgen's Repatha was shown to reduce the risk of cardiovascular events, such as cardiovascular death and myocardial infarction, in phase 3 of the FOURIER study. Full results will be presented in March 2017 at the American College of Cardiology 66th Scientific Sessions.

January 31st 2017

AHA Calls for Timing Meals to Lower Cardiovascular Risk

Mary Caffrey

Busy lifestyles are eroding the lines of traditional meal times, and all-day eating is bad for cardiovascular health, the statement says.

January 17th 2017

What's as Bad for the Heart as Obesity? Try Depression

Mary Caffrey

The study found only tobacco use and hypertension were worse on the heart than depression.

January 16th 2017

Safety of Januvia in Oldest Patients With Diabetes Confirmed in Study

Mary Caffrey

The new study in Diabetes Care comes more than a year after the initial results of the TECOS trial were presented at the American Diabetes Association Scientific Sessions.

December 2nd 2016

Jardiance Gets CV Indication for Adults With Type 2 Diabetes

Mary Caffrey

Researchers considered finding a diabetes drug that also produced a cardiovascular benefit to be a "holy grail."

November 21st 2016

Intarcia Submits New Drug Application to FDA for Diabetes Treatment

Mary Caffrey

The matchstick-size pump has been heralded as a game changer in addressing the biggest problem in diabetes care: medication adherence.

November 14th 2016

Could Vectra DA Test Be Used to Predict Cardiovascular Risk?

Patients who live with rheumatoid arthritis do not die from swollen joints but face twice the risk of suffering a heart attack or stroke.

October 26th 2016

Long-Term Exposure to Pollution Linked to Heart Disease

AJMC Staff

A new study suggests pollution particles could set into motion events like heart attacks and strokes years before they occur.

October 5th 2016

Fear of Job Loss Increases Risk of Diabetes, Study Finds

AJMC Staff

While the researchers found a "modest risk" of diabetes associated with job insecurity, they said it pointed to the need for policies that promoted job stability and better wages.

October 3rd 2016

Higher Heart Rate Linked to Increased Mortality, Hospitalization Among African Americans

Mary Caffrey

The Jackson Heart Study continues to yield insights about the nature of cardiovascular disease in minority populations.

September 27th 2016

Therapeutics Issue of Evidence-Based Diabetes Management Takes on Cost, Coverage, and Combinations

Whether it’s the high cost of insulin or the question of when to start combination therapy, the new issue of Evidence-Based Diabetes Management, a publication of The American Journal of Managed Care, covers up-to-the-minute topics in this special issue on therapeutics. Editor-in-chief Robert A. Gabbay, MD, PhD, FACP, leads off this issue featuring voices of providers, pharmaceutical leaders, payers, and patients.

September 23rd 2016

Peer Exchange: As Trials Show CV Benefits in Therapy, Panelists Discuss "Exciting Time" in Diabetes Care

Andrew Smith

Second of 2 Parts: See Part 1, in Evidence-Based Diabetes Management, coverage of Patient-Centered Diabetes Care 2016.

September 16th 2016

Novo's Semaglutide Reduces CV Risk, but Shows More Retinopathy Complications

Mary Caffrey

Results for Novo Nordisk’s semaglutide were reported today at the European Association for the Study of Diabetes. A filing for FDA approval is expected before the end of the year.

September 14th 2016

Minorities, Southerners in Medicare Less Likely to Take High Blood Pressure Medication

Mary Caffrey

The authors said this is the first study to examine antihypertension nonadherence down to the county level. Recommendations include greater use of combination therapy to reduce pill counts for patients with multiple chronic conditions, and synchronizing pharmacy visits to avoid multiple trips.

August 8th 2016

AstraZeneca Updates Digital Lifestyle Program to Include CV Health

AJMC Staff

While the online tools makes clear consumers can use it without obligation, the therapy section give patients information on AstraZeneca products.

August 5th 2016

The Financial Impact of Team-Based Care on Primary Care

Thomas E. Kottke, MD, MSPH Michael V. Maciosek, PhD Jacquelyn A. Huebsch, RN, PhD Paul McGinnis, MD Jolleen M. Nichols, RN Emily D. Parker, PhD Juliana O. Tillema, MPA

Although team-based care improved cardiovascular disease risk factors, it had a negative financial impact on a primary care practice.

August 1st 2016

Getting Ready for Bundled Payments in Cardiac Care

Mary Caffrey

Two consultants who help stakeholders in value-based transitions say CMS is serious about an aggressive pace for payment reform.

July 28th 2016

Sanofi's Lixisenatide Approved, Paving Way for OK of Combo Therapy

Mary Caffrey

The approval paves the way for Sanofi's insulin and GLP-1 combination therapy, which is due for final FDA action in August.

July 25th 2016

CMS Proposes Mandatory Bundled Payments for Cardiac Care

Mary Caffrey

This would be the second group of procedures targeted for bundled payments in Medicare. Rules for hip and knee replacements went into effect in April in 67 markets.

July 20th 2016

Patients at High Risk for Cardiovascular Events Not Taking Optimum Statin Doses

Jackie Syrop

Despite evidence and clinical guidelines that support intensive statin use in high-risk patients, very few eligible patients start treatment at recommended levels.

July 18th 2016

Impact of a Physician-Led Point of Care Medication Delivery System on Medication Adherence

Ana Palacio, MD, MPH Jessica Chen, MD Leonardo Tamariz, MD, MPH Sylvia D. Garay, MD Hua Li, PhD Olveen Carrasquillo, MD, MPH

A point of care medication delivery system improves medication adherence to cardiovascular medications without increasing costs.

July 5th 2016

FDA Panel Narrowly OKs Empagliflozin CV Benefit Claim

Mary Caffrey

If the full FDA accepts the panel's narrow recommendation, the type 2 diabetes therapy could enjoy a preferred status above its rivals in the SGLT2 market.

June 23rd 2016

Diabetes Raises Fatal Heart Attack Risk by 50%

Mary Caffrey

The study comes as regulators put increased emphasis on long-term cardiovascular outcomes trials to ensure safety of diabetes and obesity therapies. The American Journal of Managed Care recently convened an expert panel on the topic.

June 15th 2016

Value of Improved Lipid Control in Patients at High Risk for Adverse Cardiac Events

Anupam B. Jena, MD, PhD Daniel M. Blumenthal, MD, MBA Warren Stevens, PhD Jacquelyn W. Chou, MPP, MPL Thanh G.N. Ton, PhD Dana P. Goldman, PhD

Reducing lipid levels in high-risk patients can significantly reduce disease burden and, depending on final negotiated prices, PCSK9 inhibitors can make an economic contribution to this goal.

May 27th 2016

Raising the Bar on Cardiovascular Benefit

May 27th 2016

Examining Cardiovascular Outcomes Trials

May 27th 2016

GLP-1 Receptor Agonists and Cardiovascular Benefit

May 27th 2016

Understanding the Safety Data in CANVAS

May 27th 2016

Practical Implications of the CANVAS Trial

...

14 15 16 17 18 19 20 21 22 23 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions